REEGABA-NTM

REEGABA-NTM is a combination medicine primarily used for the treatment of neuropathic pain. This is chronic pain caused by nerve damage due to conditions like diabetic neuropathy, postherpetic neuralgia (shingles), or spinal cord injury.

The combination contains Pregabalin (an alpha-2 delta ligand/anti-convulsant), Nortriptyline (a tricyclic antidepressant), and Methylcobalamin (active Vitamin $ ext{B}_{12}$).

Pregabalin works by binding to calcium channels on damaged nerve cells . This action modulates nerve activity, thereby decreasing the transmission of pain signals travelling through the damaged nerves and the brain.

Nortriptyline is a tricyclic antidepressant that helps by increasing the levels of certain chemical messengers (serotonin and noradrenaline) in the brain. These messengers help to interrupt and stop pain signals, improving mood and sleep patterns associated with chronic pain.

Methylcobalamin (Vitamin $ ext{B}_{12}$) is a vital nutritional supplement that assists in the production of myelin, the protective layer around nerve fibers . This helps protect and rejuvenate damaged nerve cells.

No, you must not stop taking REEGABA-NTM suddenly, even if you feel your pain is relieved. Abrupt discontinuation can lead to withdrawal symptoms (like anxiety, nausea, or headache). The dosage must be gradually tapered as advised by your doctor.

Common side effects include dizziness, sleepiness, blurred vision, dry mouth, weight gain, and constipation. Due to potential drowsiness, do not drive or operate heavy machinery until you know how the medicine affects you.

Yes, the Pregabalin component can cause weight gain due to increased appetite. Management involves maintaining a balanced diet (avoiding high-calorie foods) and engaging in regular exercise to prevent or manage the increased weight.

No, consuming alcohol is unsafe while taking REEGABA-NTM. Alcohol can significantly increase the side effects of dizziness, drowsiness, and sleepiness, leading to potential impairment and risk.

Patients and caregivers should monitor for unusual changes in mood or behavior, including new or worsening depression or the emergence of suicidal thoughts. This should be immediately reported to a healthcare professional.